 Healio | Inotuzumab/rituximab combination shows promise in NHL Healio The phase 1/2 study aimed to determine the maximum tolerated dose of inotuzumab ozogamicin plus rituximab (Rituxan, Genentech/Idec Pharmaceuticals) in a cohort of patients with relapsed/refractory CD20+/CD22+ B-cell non-Hodgkin's lymphoma. |
